Barr (BRL : 
BRL54.08, +0.55, +1.0% ) slid 3% to close at $53.53 on word that the Food and Drug Administration had granted Watson (WPI : ![]()
WPI26.02, +0.29, +1.1% ) final approval to put out a generic version of Barr's Seasonale oral contraceptive. Watson, which plans to market the product under the name Quasense, said the contraceptive had sales of $110 million for the twelve months ended June 2006.
Barr Laboratories, Inc.
Last: 54.08+0.55+1.03%
4:02pm 09/08/2006
Delayed quote data
4:02pm 09/08/2006
Delayed quote data
Sponsored by:
Watson Pharmaceuticals Inc
Last: 26.02+0.29+1.13%
4:01pm 09/08/2006
Delayed quote data
4:01pm 09/08/2006
Delayed quote data
Sponsored by:
Watson closed nominally higher at $25.73.
This is interesting. I am following this as far as the science behind the drug and the legal issues. More to come once the US Market opens on Monday. I'll post the pharmacology ASAP.
This is interesting. I am following this as far as the science behind the drug and the legal issues. More to come once the US Market opens on Monday. I'll post the pharmacology ASAP.
No comments:
Post a Comment